alefacept
Sign in to saveAlso known as BG-9712, BG-9273, Amevive, ASP0485, Lfa3Tip
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc., the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic dise
Research
480 papers- Alefacept.2012
- Alefacept.American journal of clinical dermatology · 2003
- Alefacept (Biogen).Current opinion in investigational drugs (London, England : 2000) · 2001
- Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.The Journal of dermatological treatment · 2007
- Alefacept: a safety profile.Expert opinion on drug safety · 2005
via PubMed
Wikidata facts
Show 1 more fact
- chemical formula
- C₂₃₀₆H₃₅₉₄N₆₁₀O₆₉₄S₂₆
Sources (2)
via Wikidata · CC0
~7 min read
Article
12 sectionsContents
- Mechanism of action
- Indications
- Contraindications and precautions
- Pregnancy and lactation
- Pediatric patients
- Side effects
- Interactions
- Necessary laboratory examinations
- Dosage regimens
- Withdrawal
- Notes
- External links
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc., the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.
Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation. It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.
Available in 11 languages
via Wikidata sitelinks · CC0